Risperidone extended release (Lyndra)

利培酮缓释制剂 (Lyndra)

Report date: 2025/02/10 15:37:12

Base Information

Drug NameRisperidone extended release (Lyndra)
Drug Alias Name口服超长效利培酮LYN-005
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D2 receptor antagonistsSerotonin 2a (5-HT2a) receptor antagonists
TargetsDopamine D2 receptorSerotonin 2a (5-HT2a) receptor
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesLyndra Inc
China Registration ClassN/A

Develop Information

Active CompaniesLyndra Therapeutics IncLyndra Inc
Inactive CompaniesN/A
Active IndicationsSchizophrenia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A